DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

He, Yonghan; Koch, Raphael; Budamagunta, Vivekananda; Zhang, Peiyi; Zhang, Xuan; Khan, Sajid; Thummuri, Dinesh; Ortiz, Yuma T.; Zhang, Xin; Lv, Dongwen; Wiegand, Janet S.; Li, Wen; Palmer, Adam C.; Zheng, Guangrong; Weinstock, David M.; Zhou, Daohong

doi:10.1186/s13045-020-00928-9

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

Background Patients with advanced T cell lymphomas (TCLs) have limited therapeutic options and poor outcomes in part because their TCLs evade apoptosis through upregulation of anti-apoptotic Bcl-2 proteins. Subsets of TCL cell lines, patient-derived xenografts (PDXs), and primary patient samples …